New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 1000mg;  ;   - coated tablet - 1000 mg - active: metformin hydrochloride 1000mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 250mg - coated tablet - 250 mg - active: metformin hydrochloride 250mg excipient: magnesium stearate opadry clear oy-29020 povidone water

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 500mg;  ;   - coated tablet - 500 mg - active: metformin hydrochloride 500mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 850mg;  ;   - coated tablet - 850 mg - active: metformin hydrochloride 850mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: arrow - cabergoline is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2. after stillbirth or abortion. treatment of hyperprolactinaemic disorders: cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bimatoprost 0.1 mg/ml;   - eye drops, solution - 0.1 mg/ml - active: bimatoprost 0.1 mg/ml   excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - bimatoprost actavis is indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - bimatoprost actavis is indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefoxitin sodium 1 g - powder for injection - 1 g - active: cefoxitin sodium 1 g - cefoxitin actavis is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. cefoxitin actavis has a high degree of stability against beta-lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin actavis can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefoxitin sodium 2 g - powder for injection - 2 g - active: cefoxitin sodium 2 g - cefoxitin actavis is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. cefoxitin actavis has a high degree of stability against beta-lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin actavis can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cetirizine hydrochloride 10mg;   - film coated tablet - 10 mg - active: cetirizine hydrochloride 10mg   excipient: benzyl alcohol calcium hydrogen phosphate dihydrate hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone purified talc   sodium starch glycolate titanium dioxide - cetirizine is indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis. symptoms treated effectively include sneezing,rhinorrhea,post-nasal discharge, nasal pruritus, ocular pruritus and tearing. cetirizine is also indicated for the treatment of: · allergic conjunctivitis; · insect bites and the uncomplicated skin manifestations of chronic idiopathic urticaria. it significantly reduces the occurrence, severity and duration of hives and markedly reduces pruritus.